Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.75 |
| ▸ | RAB9A | P51151 | 11/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | STAT1 | P42224 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | ALPL | P05186 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ACP1 | P24666 | 1/20 | 0.59 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18585932 | 0.86 | NPC1 (0.77) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL29973978 | 0.84 | NPC1 (0.74) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL6057541 | 0.84 | NPC1 (1.00) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL28878441 | 0.84 | NPC1 (0.74) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL23628959 | 0.82 | GSK3B (0.54) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL23628970 | 0.82 | SMN1; SMN2 (0.54) | NPC1SMN1; SMN2RAB9AALDH1A1KDM4E | |
| SCHEMBL14159072 | 0.81 | NPC1 (0.65) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL4746072 | 0.81 | NPC1 (0.77) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL14808429 | 0.81 | SMN1; SMN2 (0.77) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 | |
| SCHEMBL11303998 | 0.81 | NPC1 (0.80) | NPC1SMN1; SMN2RAB9AALDH1A1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | UNIVERZA V LJUBLJANI (SI) | 2025-03-25 | — | — | US | disclosed |
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | UNIVERZA V LJUBLJANI (SI) | 2021-10-21 | — | — | US | disclosed |
| EP-3847172-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | Univerza v Ljubljani (SI) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOP1, TOP2A, TOP2B | NPC1 4573/4885SMN1; SMN2 4589/4885RAB9A 3897/4885 |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | TOP1, TOP2A, TOP2B | NPC1 4546/4885SMN1; SMN2 4529/4885RAB9A 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.